Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7546 to 7560 of 8938 results

  1. VitalPAC for assessing vital signs of patients in hospital (MIB79)

    This advice has been updated and replaced by NICE medtech innovation briefing 205.

    Withdrawn advice

  2. UrgoStart for chronic wounds (MIB82)

    This advice has been updated and replaced by NICE medical technologies guidance 42.

    Withdrawn advice

  3. Absorb Bioresorbable Vascular Scaffold system for coronary artery disease (MIB84)

    NICE withdrew this medtech innovation briefing in November 2017 after the company stopped manufacturing Absorb because of low uptake. Some UK hospitals continue to use the technology in ongoing clinical studies.

    Withdrawn advice

  4. TheraSphere for treating operable and inoperable hepatocellular carcinoma (MIB62)

    This medtech innovation briefing has been updated and replaced by NICE technology appraisal guidance 688.

    Withdrawn advice

  5. SIR-Spheres for treating inoperable hepatocellular carcinoma (MIB63)

    This medtech innovation briefing has been updated and replaced by NICE technology appraisal guidance 688.

    Withdrawn advice

  6. Intramedullary distraction for lower limb lengthening (IPG197)

    This guidance has been updated and replaced by NICE HealthTech guidance 613.

    Withdrawn guidance

  7. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA111)

    This guidance has been updated and replaced by NICE technology appraisal 217.

    Withdrawn guidance

  8. Implantable cardioverter defibrillators (ICDs) for the treatment of arrhythmias (TA11)

    This guidance has been replaced by NICE technology appraisal guidance 95 [Replaced by NICE technology appraisal guidance 314]. 

    Withdrawn guidance

  9. Rituximab for the treatment of follicular lymphoma (TA110)

    This guidance has been updated and replaced by NICE technology appraisal guidance 243.

    Withdrawn guidance

  10. Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia (TA344)

    This guidance has been withdrawn because Novartis has discontinued ofatumumab (Arzerra). Ofatumumab will continue to be available for people who need it. Contact Clinigen at managedacess@clinigengroup.com or 01932 842100 for details.

    Withdrawn guidance

  11. Carfilzomib for previously treated multiple myeloma (TA457)

    This technology appraisal guidance has been updated and replaced by NICE technology appraisal guidance 657 

    Withdrawn guidance

  12. Collagenase clostridium histolyticum for treating Dupuytren's contracture (TA459)

    We have withdrawn the guidance because collagenase clostridium histolyticum (Xiapex) is no longer available in the UK.

    Withdrawn guidance

  13. The clinical effectiveness and cost effectiveness of surgery for people with morbid obesity (TA46)

    This guidance has been updated and replaced by NICE guideline CG43.

    Withdrawn guidance

  14. Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma (TA465)

    This guidance has been withdrawn because olaratumumab (Lartruvo) no longer has a marketing authorisation.

    Withdrawn guidance

  15. Idelalisib for treating follicular lymphoma that is refractory to 2 prior treatments (terminated appraisal) (TA328)

    This guidance has been updated and replaced by NICE technology appraisal guidance 604.

    Withdrawn guidance